Immunic, Inc. (IMUX)

NCM – Real Time Price. Currency in USD

11.90

-0.10 (-0.83%)

At close: May 12, 2026, 4:00 PM EDT

11.95

+0.05 (0.40%)

Pre-market: May 13, 2026, 7:41 AM EDT

13.05.2026

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D.

12.05.2026

Immunic: Saved By A 200 Million Private Placement

Immunic, Inc. (IMUX) is rated Hold due to high cash burn, heavy dilution, and reliance on a single near-term catalyst. Vidofludimus calcium (IMU-838) Phase 3 MS trial results, expected late 2026, are pivotal for IMUX's future revenue and valuation. Recent $187M private placement and $200M in warrants extend IMUX's cash runway to Phase 3 readout, and hopefully to the drugs rollout to the market, reducing near-term dilution risk.

30.04.2026

Immunic to Participate in Investor and Medical Conferences in May

NEW YORK, April 30, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor and medical conferences in May: May 4-6 and 12-13: 26th Bio€quity Europe. Daniel Vitt, Ph.D.

28.04.2026

Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout

Immunic Inc (NASDAQ:IMUX, FRA:10VA) has named Michael A. Panzara as Chief Medical Officer, bringing aboard a veteran neurologist with more than 25 years of drug development experience as the biotechnology company braces for a critical clinical milestone in multiple sclerosis.

28.04.2026

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

– Proven Leader in Neurology Drug Development, Including for Several Approved MultipleSclerosis Therapies – – Strong Experience in Advancing Late-Stage Clinical Programs and Obtaining Global Regulatory Approvals, Key to Supporting Vidofludimus Calcium Through Pivotal Development – NEW YORK, April 28, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael A. Panzara, M.D.

23.04.2026

Immunic to implement 1-for-10 reverse stock split

Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced it will implement a 1-for-10 reverse stock split of its common shares, effective April 27, as part of efforts to meet contractual obligations tied to a recent securities agreement. The reverse split will take effect at 12:01 a.m.

23.04.2026

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

NEW YORK, April 23, 2026 /PRNewswire/ -- Immunic , Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases (the "Company" or "Immunic"), today announced that it will effect a reverse stock split of its outstanding shares of common stock, effective as of 12:01 a.m. Eastern Time on April 27, 2026.

Videos

No Data

There is no data to display

Press releases

13.05.2026

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

– Appointed Globally Renowned Biopharmaceutical Executive and Neurology Drug Developer, Michael A. Panzara, M.D.

30.04.2026

Immunic to Participate in Investor and Medical Conferences in May

28.04.2026

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

23.04.2026

Immunic, Inc. (IMUX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Immunic, Inc. (IMUX)

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic: Saved By A 200 Million Private Placement

Immunic to Participate in Investor and Medical Conferences in May

Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Immunic to implement 1-for-10 reverse stock split

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Videos

No Data

Press releases

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic to Participate in Investor and Medical Conferences in May

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic: Saved By A 200 Million Private Placement

Immunic to Participate in Investor and Medical Conferences in May

Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Immunic to implement 1-for-10 reverse stock split

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Videos

No Data

Press releases

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic to Participate in Investor and Medical Conferences in May

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Search stocks

Immunic, Inc. (IMUX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Immunic, Inc. (IMUX)

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic: Saved By A 200 Million Private Placement

Immunic to Participate in Investor and Medical Conferences in May

Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Immunic to implement 1-for-10 reverse stock split

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Videos

No Data

Press releases

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic to Participate in Investor and Medical Conferences in May

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic: Saved By A 200 Million Private Placement

Immunic to Participate in Investor and Medical Conferences in May

Immunic appoints Michael Panzara as CMO ahead of pivotal MS drug readout

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Immunic to implement 1-for-10 reverse stock split

Immunic, Inc. Announces 1-for-10 Reverse Stock Split

Videos

No Data

Press releases

Immunic, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

Immunic to Participate in Investor and Medical Conferences in May

Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D.

Immunic, Inc. Announces 1-for-10 Reverse Stock Split